Genetic Polymorphism in ATG16L1 Gene Influences the Response to Adalimumab in Crohn’s Disease Patients
Copyright policy )Genetic Polymorphism in ATG16L1 Gene Influences the Response to Adalimumab in Crohn’s Disease Patients
To see if SNPs could help predict response to biological therapy using adalimumab (ADA) in Crohn's disease (CD).IBDQ index and CRP levels were used to monitor therapy response. We genotyped 31 CD-associated genes in 102 Slovenian CD patients.The strongest association for treatment response defined as decrease in CRP levels was found for ATG16L1 SNP rs10210302. Additional SNPs in 7 out of 31 tested CD-associated genes (PTGER4, CASP9, IL27, C11orf30, CCNY, IL13, NR1I2) showed suggestive association with ADA response.Our results suggest ADA response in CD patients is genetically predisposed by SNPs in CD risk genes and suggest ATG16L1 as most promising candidate gene for drug response in ADA treatment. Original submitted 24 September 2014; Revision submitted 1 December 2014.
- University Medical Center Groningen Netherlands
- University Medical Centre Ljubljana Slovenia
- University of Ljubljana Slovenia
- University of Maribor Slovenia
- University of Groningen Netherlands
Adult, Genetic Markers, Male, SUSCEPTIBILITY LOCI, Genotype, EXTRAINTESTINAL MANIFESTATIONS, Slovenia, Autophagy-Related Proteins, Polymorphism, Single Nucleotide, Crohn Disease, single nucleotide polymorphism, MODULATES EXPRESSION, adalimumab, Humans, GENOME-WIDE ASSOCIATION, Genetic Association Studies, pharmacogenomics, Tumor Necrosis Factor-alpha, MELTING CURVE ANALYSIS, Adalimumab, Middle Aged, INFLIXIMAB THERAPY, Crohn's disease, RECEPTOR GENE, CLINICAL REMISSION, C-Reactive Protein, Treatment Outcome, ULCERATIVE-COLITIS, Female, Carrier Proteins, biological drugs, INFLAMMATORY-BOWEL-DISEASE
Adult, Genetic Markers, Male, SUSCEPTIBILITY LOCI, Genotype, EXTRAINTESTINAL MANIFESTATIONS, Slovenia, Autophagy-Related Proteins, Polymorphism, Single Nucleotide, Crohn Disease, single nucleotide polymorphism, MODULATES EXPRESSION, adalimumab, Humans, GENOME-WIDE ASSOCIATION, Genetic Association Studies, pharmacogenomics, Tumor Necrosis Factor-alpha, MELTING CURVE ANALYSIS, Adalimumab, Middle Aged, INFLIXIMAB THERAPY, Crohn's disease, RECEPTOR GENE, CLINICAL REMISSION, C-Reactive Protein, Treatment Outcome, ULCERATIVE-COLITIS, Female, Carrier Proteins, biological drugs, INFLAMMATORY-BOWEL-DISEASE
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).60 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!